August 7, 2026- QuidelOrtho Corporation announced financial results for the second quarter ended June 28, 2026.
Key Second Quarter 2026 Results:
(all comparisons are to the prior year period)
- Total revenue was $631 million, an increase of 3% as reported and 2% in constant currency. Excluding China, total revenue grew 6% both as reported and in constant currency.
- Labs revenue of $383 million grew by 4% as reported and 2% in constant currency. Growth was driven by continued strength across the core business and partially offset by slower sales in China, which the Company believes is primarily related to recently announced changes to In Vitro Diagnostics pricing. Outside of China, Labs revenue grew 9% both as reported and in constant currency.
- Immunohematology revenue of $134 million grew 1% both as reported and in constant currency. Outside of China, Immunohematology revenue grew 5% both as reported and in constant currency.
- Point of Care revenue of $108 million grew 16% both as reported and in constant currency, including Triage revenue growth of 10% as reported and 9% in constant currency.
- GAAP net loss was $93 million; GAAP operating loss was $22 million; adjusted EBITDA was $129 million.
- GAAP net loss margin was 14.7%; GAAP operating loss margin was 3.5%; adjusted EBITDA margin was 20.5%, an improvement of 310 basis points.
- GAAP diluted loss per share was $1.36; adjusted diluted earnings per share (“EPS”) was $0.13.